NovaBay Pharmaceuticals, Inc. Form DEFA14A May 18, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _____)

Filed by the Registrant x	
Filed by a Party other than the Registrant	t o

Check the appropriate box:

- o Preliminary Proxy Statement
- o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- o Definitive Proxy Statement
- x Definitive Additional Materials
- o Soliciting Material Pursuant to §240.14a-12

NovaBay Pharmaceuticals, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- x No fee required.
- o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:

- (5) Total fee paid:
- o Fee paid previously with preliminary materials.
- O Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:

NOVABAY PHARMACEUTICALS, INC.

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS TO BE HELD JUNE 16, 2010

To the Shareholders of NovaBay Pharmaceuticals, Inc.:

The following supplements our Proxy Statement sent to you in connection with the NovaBay Pharmaceuticals, Inc. 2010 Annual Meeting of Shareholders. Appendix B of the Proxy Statement is revised to reflect, as described in the Proxy Statement, that:

- 1. The Board of Director has the power to amend the Bylaws of NovaBay (Delaware), which Bylaws may only be amended by a vote of 66 2/3% of the outstanding shares of NovaBay (Delaware); and
- 2. That the stockholders of NovaBay (Delaware) cannot act by unanimous written consent.

These provisions already appear in the Bylaws of NovaBay (Delaware), and have been added to the provisions of the Certificate of Incorporation of NovaBay Delaware to ensure their enforceability.

Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on Wednesday, June 16, 2010.

The proxy statement, proxy statement supplement and annual report to security holders are available at www.envisionreports.com/NBY (for registered Shareholders only) and www.edocumentview.com/NBY (for all Shareholders).

By Order of the Board of Directors,

/s/ Ramin Najafi, Ph.D. Ramin ("Ron") Najafi, Ph.D. Chairman of the Board, Chief Executive Officer and President

May 17, 2010

Appendix B

Form of Certificate of Incorporation of NovaBay (Delaware) to be effective after the Reincorporation

CERTIFICATE OF INCORPORATION OF NOVABAY PHARMACEUTICALS, INC.

The undersigned, a natural person (the "Sole Incorporator"), for the purpose of organizing a corporation to conduct the business and promote the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware hereby certifies that:

I.

The name of this corporation is NovaBay Pharmaceuticals, Inc. (the "Corporation").

II.

The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of Newcastle and the name of the registered agent of the Corporation in the State of Delaware at such address is The Corporation Trust Company.

III.

The purpose of this Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law ("DGCL").

IV.

A. This Corporation is authorized to issue two classes of stock to be designated, respectively, "Common Stock" and "Preferred Stock." The total number of shares which the Corporation is authorized to issue is Seventy Million (70,000,000) shares. Sixty-Five Million (65,000,000) shares shall be Common Stock, each having a par value of one cent (\$0.01) per share. Five Million (5,000,000) shares shall be Preferred Stock, each having a par value of one cent (\$0.01) per share.

B. The Preferred Stock may be issued from time to time in one or more series without further stockholder approval. The Board of Directors is hereby expressly authorized to provide for the issue of all or any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of the stock of the Corporation entitled to vote thereon, without a

separate vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any certificate of designation filed with respect to any series of Preferred Stock.

C. Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation (including any certificate of designation filed with respect to any series of Preferred Stock).

V.

For the management of the business and for the conduct of the affairs of the Corporation, and in further definition, limitation and regulation of the powers of the Corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that:

A. Management of the Business. The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of Directors. [Alternative 1 to be used if the shareholders of the Company approve Proposal 4: "The number of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the Board of Directors."][Alternative 2 to be used if the shareholders of the Company do not approve Proposal 4: "The number of directors to constitute the whole board of directors shall not be less than nine (9) nor more than eleven (11), and the exact number of directors shall be fixed within these specified limits by the board of directors in the manner provided in the Bylaws."]

B.Election of Directors. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the directors shall be divided into three classes designated as Class I, Class II and Class III, respectively. At the annual meeting of stockholders in 2011, the term of office of the Class I directors shall expire and Class I directors shall be elected for a full term of three years. At the annual meeting of stockholders in 2012, the term of office of the Class II directors shall expire and Class III directors shall be elected for a full term of three years. At the annual meeting of stockholders in 2013, the term of office of the Class III directors shall expire and Class III directors shall be elected for a full term of three years. At each succeeding annual meeting of stockholders, directors shall be elected for a full term of three years to succeed the directors of the class whose terms expire at such annual meeting.

Notwithstanding the foregoing provisions of this section, each director shall serve until his successor is duly elected and qualified or until his earlier death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.

C. Vacancies. Subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors may, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director's successor shall have been elected and qualified.

D.Action by Stockholders. No action shall be taken by the stockholders except at an annual or special meeting of stockholders called in accordance with the Bylaws of the Corporation, and no action shall be taken by the stockholders by written consent or by electronic transmission.

E.Bylaw Amendments. The Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the Bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt, amend or repeal any provision of the Bylaws of the Corporation.

VI.

A. The liability of the directors for monetary damages shall be eliminated to the fullest extent under applicable law. If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated to the fullest extent permitted by the DGCL, as so amended.

B. Any repeal or modification of this Article VI shall be prospective and shall not affect the rights under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.


VII.

A. The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as provided in paragraph B. of this Article VII, and all rights conferred upon the stockholders herein are granted subject to this reservation.

B. Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the Corporation required by law or by this Certificate of Incorporation or any certificate of designation filed with respect to a series of Preferred Stock, the affirmative vote of the holders of at least sixty-six and two thirds percent (66 2/3%) of the voting power of all of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to alter, amend or repeal paragraphs B, D or E of Article V or this Article VII.

	VIII.				
The name and the mailing address of the Sol	le Incorporator is as follows:				
Name	Mailing Address				
Theresa Granados-Uriarte	NovaBay Pharmaceuticals, Inc. 5890 Horton Street, Suite 550 Emeryville, CA 94608				
In Witness Whereof, this Certificate has been subscribed this day of, 2010 by the undersigned who affirms that the statements made herein are true and correct.					
Theresa Granados-Uriarte Sole Incorporator					
6 IGN=BOTTOM>					

0.0%



12

TYPE OF REPORTING PERSON*

PN

* SEE INSTRUCTIONS BEFORE FILLING OUT!

CUS	IP NO. 92932M101			13 G			Pag	e 4 of 12
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Tiger Global, L.P. (Tiger Global)							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				(a)	0	(b)	x
3	SEC USE ONLY							
4	CITIZENSHIP OR PLA Delaware	ACE OF	ORGANIZATION					
	NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares.					
	OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER See response to row 5.					
		7	SOLE DISPOSITIVE POWER 0 shares.					
		8	SHARED DISPOSITIVE POWER See response to row 7.					
9	9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				0			
10	10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* o							
11					0.0%			
12	12 TYPE OF REPORTING PERSON* PN							
	* SEE INSTRUCTIONS BEFORE FILLING OUT!							

CUSI	JSIP NO. 92932M101		1	13 G			Pag	ge 5 of 12
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Tiger Global Performance, L.L.C. (Tiger Global Performance)							
2	CHECK THE APPROP	RIATE	BOX IF A MEMBER OF A GROUP*		(a)	o	(b)	x
3	SEC USE ONLY							
4	CITIZENSHIP OR PLA Delaware	CE OF	ORGANIZATION					
	NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares.					
	OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER See response to row 5.					
		7	SOLE DISPOSITIVE POWER 0 shares.					
		8	SHARED DISPOSITIVE POWER See response to row 7.					
9	9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0					0		
10	0 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 0							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.0%							
12	2 TYPE OF REPORTING PERSON* OO							
	* SEE INSTRUCTIONS BEFORE FILLING OUT!							

CUS	P NO. 92932M101		13	G			Page	e 6 of 12
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Tiger Global, Ltd. (Tiger Ltd.)							
2	2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*				(a)	0	(b)	x
3	SEC USE ONLY							
4	CITIZENSHIP OR PLA Cayman Islands	ACE OF	ORGANIZATION					
	NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares.					
	OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER See response to row 5.					
		7	SOLE DISPOSITIVE POWER 0 shares.					
		8	SHARED DISPOSITIVE POWER See response to row 7.					
9	AGGREGATE AMOU REPORTING PERSON		NEFICIALLY OWNED BY EACH			0		
10	10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 0							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9				0.0%			
12	2 TYPE OF REPORTING PERSON*				СО			
* SEE INSTRUCTIONS BEFORE FILLING OUT!								

CUS	IP NO. 92932M101		1:	3 G			Pag	e 7 of 12
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Charles P. Coleman III (Coleman)							
2	CHECK THE APPROP	PRIATE	BOX IF A MEMBER OF A GROUP*	(a	a)	0	(b)	x
3	SEC USE ONLY							
4	CITIZENSHIP OR PLA U.S. Citizen	ACE OF	ORGANIZATION					
	NUMBER OF SHARES BENEFICIALLY	5	SOLE VOTING POWER 0 shares.					
	OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER See response to row 5.					
		7	SOLE DISPOSITIVE POWER 0 shares.					
		8	SHARED DISPOSITIVE POWER See response to row 7.					
9	9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0				0			
10	0 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 0							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.0%							
12	12 TYPE OF REPORTING PERSON* IN							
	* SEE INSTRUCTIONS BEFORE FILLING OUT!							

CUSIP NO. 92932M101 13 G Page 8 of 12

This Amendment No. 2 amends the Schedule 13G filed with the Securities and Exchange Commission on September 26, 2006, as amended by Amendment No. 1 on February 12, 2009 by Charles P. Coleman III (Coleman), Tiger Global Management, LLC, a Delaware limited liability company (Tiger Management), Tiger Global II, L.P., a Delaware limited partnership, Tiger Global, L.P., a Delaware limited partnership, Tiger Global Performance, L.L.C., a Delaware limited liability company, and Tiger Global, Ltd., a Cayman Islands exempted company, and amends the Schedule 13G filed by Coleman and Tiger Management. The foregoing entities and individual are collectively referred to as the Reporting Persons. Only those items as to which there has been a change are included in this Amendment No. 2.

ITEM 4. <u>OWNERSHIP</u>

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

See Row 9 of cover page for each Reporting Person.

(b) Percent of Class:

See Row 11 of cover page for each Reporting Person.

- (c) Number of shares as to which such person has:
 - (i) Sole power to vote or to direct the vote:

See Row 5 of cover page for each Reporting Person.

(ii) Shared power to vote or to direct the vote:

See Row 6 of cover page for each Reporting Person.

(iii) Sole power to dispose or to direct the disposition of:

See Row 7 of cover page for each Reporting Person.

(iv) Shared power to dispose or to direct the disposition of:

See Row 8 of cover page for each Reporting Person.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following: x

CUSIP NO. 92932M101 13 G Page 9 of 12

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 12, 2010

Tiger Global Management, L.L.C. /s/ Charles P. Coleman III

Signature

Charles P. Coleman III Managing Member

Tiger Global II, L.P. /s/ Charles P. Coleman III

By Tiger Global Performance, L.L.C. Signature

Its General Partner

Charles P. Coleman III Managing Member

Tiger Global, L.P. /s/ Charles P. Coleman III

By Tiger Global Performance, L.L.C. Signature

Its General Partner

Charles P. Coleman III Managing Member

Tiger Global, Ltd. /s/ Charles P. Coleman III

Signature

Charles P. Coleman III

Director

Tiger Global Performance, L.L.C. /s/ Charles P. Coleman III

Signature

Charles P. Coleman III Managing Member

Charles P. Coleman III /s/ Charles P. Coleman III

Signature

CUSIP NO. 92932M101 13 G Page 10 of 12

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. *See* §240.13d-7 for other parties for whom copies are to be sent.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

CUSIP NO.	92932M101	13 G EXHIBIT INDEX	Page 11 of 12
			Found on Sequentially
Exhibit			Numbered Page
Exhibit A:	Agreement of Joint Filing		12

CUSIP NO. 92932M101 13 G Page 12 of 12

EXHIBIT A

Agreement of Joint Filing

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary Shares of WNS (Holdings) Limited shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G (or any amendment thereto).

Date: February 12, 2010

Tiger Global II, L.P. /s/ Charles P. Coleman III

By Tiger Global Performance, LLC Signature

Its General Partner

Charles P. Coleman III Managing Member

Tiger Global, L.P. /s/ Charles P. Coleman III

By Tiger Global Performance, L.L.C. Signature

Its General Partner

Charles P. Coleman III Managing Member

Tiger Global Performance, L.L.C. /s/ Charles P. Coleman III

Signature

Charles P. Coleman III Managing Member

Tiger Global, Ltd. /s/ Charles P. Coleman III

Signature

Charles P. Coleman III

Director

Tiger Global Management, LLC /s/ Charles P. Coleman III

Signature

Charles P. Coleman III Managing Member

Charles P. Coleman III /s/ Charles P. Coleman III

Signature